TrivarX Limited (AU:TRI)
ASX:TRI
Want to see AU:TRI full AI Analyst Report?
Top Page
TrivarX Limited
(Sydney:TRI)
Select Model
Select Model
Rating:49Neutral
Price Target:
AU$0.03
▲(25.00% Upside)
Action:Reiterated
Date:05/21/26
The score is held down primarily by weak financial performance (continued losses, negative operating/free cash flow, and zero reported revenue), partially offset by a low-debt balance sheet. Technicals are relatively strong with price above major moving averages and positive momentum, but near-overbought readings add risk. Valuation remains unattractive due to negative earnings and no dividend support.
Positive Factors
Conservative balance sheet
An extremely low debt-to-equity ratio and a multi-million equity cushion materially reduce financial distress risk and extend strategic optionality. This durable capital base supports continued product development or clinical/market activities despite operating losses, improving survival odds.
Negative Factors
Zero reported revenue
Having no reported revenue is a fundamental constraint: it prevents assessment of demand, unit economics, or scalable margins. Over a multi-month horizon this raises execution risk, as the company must demonstrate commercial adoption before losses can be sustainably reversed.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
An extremely low debt-to-equity ratio and a multi-million equity cushion materially reduce financial distress risk and extend strategic optionality. This durable capital base supports continued product development or clinical/market activities despite operating losses, improving survival odds.
Read all positive factors
TrivarX Limited (TRI) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$32.30M
Dividend YieldN/A
Average Volume (3M)1.22M
Price to Earnings (P/E)―
Beta (1Y)2.72
Revenue GrowthN/A
EPS Growth-260.00%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,153,693,500
10 Day Avg. Volume1,871,965
30 Day Avg. Volume1,217,195
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-54.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TrivarX Limited Business Overview & Revenue Model
Company Description
Operating as a health technology enterprise, TrivarX Limited specializes in crafting artificial intelligence-driven, scientifically validated instruments designed for the assessment and identification of behavioral health disorders. Its market pre...
TrivarX Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
68
Positive
Cash Flow
22
Negative
| Breakdown | Jun 2024 | Jun 2023 |
|---|---|---|
Income Statement | ||
| Total Revenue | 0.00 | 0.00 |
| Gross Profit | -52.47K | 0.00 |
| EBITDA | -1.89M | -1.13M |
| Net Income | -943.23K | -1.24M |
Balance Sheet | ||
| Total Assets | 13.48M | 10.81M |
| Cash, Cash Equivalents and Short-Term Investments | 1.25M | 848.10K |
| Total Debt | 169.03K | 15.90K |
| Total Liabilities | 831.22K | 1.18M |
| Stockholders Equity | 12.65M | 9.88M |
Cash Flow | ||
| Free Cash Flow | -189.74K | -3.70M |
| Operating Cash Flow | -189.74K | 0.00 |
| Investing Cash Flow | -2.09M | -2.85M |
| Financing Cash Flow | 2.68M | 4.32M |
TrivarX Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$19.08M | 26.43 | 7.57% | ― | 31.36% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$32.30M | -14.30 | -7.84% | ― | ― | -260.00% | |
46 Neutral | AU$17.17M | ― | -578.72% | ― | 43.55% | 26.03% | |
44 Neutral | AU$23.07M | -7.62 | -1122.02% | ― | ― | ― | |
43 Neutral | AU$27.17M | -3.94 | -1009.84% | ― | 13.69% | 7.57% | |
40 Underperform | AU$12.43M | -0.18 | -137.16% | ― | -71.80% | -1044.71% |
* Healthcare Sector Average
AU:TRI
TrivarX Limited
0.03
0.02
180.00%
AU:RHT
Resonance Health Ltd
0.04
>-0.01
-6.98%
AU:PKY
Opyl Ltd.
0.04
0.02
100.00%
AU:AHE
MedAdvisor Limited
0.02
-0.06
-77.11%
AU:ICR
InteliCare Holdings Limited
0.02
0.01
71.43%
AU:PCK
PainChek Ltd
0.13
-0.26
-66.67%
TrivarX Limited Corporate Events
TrivarX Shifts Registered Office to Hawthorn East Advisory Hub
May 26, 2026
TrivarX Limited has changed its registered office and principal place of business to Suite 1.01, 117 Camberwell Road in Hawthorn East, Victoria, under the care of Bio101 Financial Advisory. The move, authorised by the board, aligns the ASX-listed ...
TrivarX taps CRO Beyond to launch Phase 1 trial of Stabl-Im imaging platform
May 22, 2026
TrivarX Limited has engaged specialist Contract Research Organisation Beyond Drug Development to advance the planned Phase 1 safety trial of its Stabl-Im MRI-based functional imaging platform. The initial mandate covers completion of the clinical ...
TrivarX Sharpens Focus on Stabl-Im Trials and Appoints New CEO to Drive Commercial Push
Apr 30, 2026
TrivarX advanced development of its Stabl-Im brain imaging technology during the March quarter, refining Phase 1 clinical trial design, progressing manufacturing validation, and initiating early regulatory planning in the U.S. and Europe. The comp...
TrivarX names new CEO to advance Stabl-Im brain cancer imaging platform
Apr 28, 2026
TrivarX has appointed radiopharmaceutical and biotech veteran Dr Danielle Meyrick as chief executive officer from 1 June 2026 to lead clinical and commercial development of its Stabl-Im brain cancer imaging platform. With more than two decades in ...
TrivarX reshapes leadership and governance to drive digital health commercialisation
Mar 4, 2026
TrivarX has terminated the employment of Chief Medical Officer Dr Archie Defillo, who played a key role in developing its MEB-001 and single-channel ECG algorithms, as the company shifts toward a more commercially focused phase. To drive this tran...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.